Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This upward trajectory coincides with positive developments in its HIV treatment ...

Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on Retroviruses and Opportunistic Infections (CROI 2025). ALLIANCE is an ongoing ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV prevention drug lenacapavir allows it to persist in the body for up to a year.

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...

In the second trial, which was open label, 95.6% of participants who switched to DOR/ISL maintained viral suppression ...

Phase 1 Data Indicate Potential for Use of Once-Yearly Lenacapavir for HIV Prevention, with Plans to Launch a Phase 3 Trial in 2H 2025 – ...

A Lancet study shows promising results for an annual HIV prevention injection, lenacapavir. In Stage 1 trials, 40 HIV-negative participants had no significant side effects ...

A yearly injection to protect against HIV is safe and shows promise as a prevention method with long-lasting effects, according to the results of a c ...

Upland Software, Inc. , a leader in cloud-based tools for digital transformation, today announced financial and operating results for the fourth quarter 2024 and issued guidance for its first quarter ...